ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

blinatumomab

Also written as “Blinatumomab”, “MEDI-538” and “Blinatumomab (MT103)”.

Its studies are mostly in Precursor Cell Lymphoblastic Leukemia-Lymphoma · Lymphoma, Large B-Cell, Diffuse · Neoplasm, Residual · Lymphoma, Non-Hodgkin · Lymphoma, B-Cell, led by 4 companies.

Drug pageBlinatumomab: every studyAll 128 studies of it, academic ones too, with its approvals, label and forms.
Furthest: phase 4, since Jul 27, 202029 company-led studies, 7 open or runningNext primary completion: Nov 24, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Amgenits history only256 open or runningphase 4since Jul 27, 2020Jan 10, 2006Nov 24, 2027phase 2 · NCT04521231
AstraZenecaits history only20 open or runningphase 2since May 8, 2008Sep 28, 2007none ahead
Imugene10 open or runningphase 1since Sep 14, 2023Sep 14, 2023none ahead
Novartisits history only11 open or runningphase 2since Jan 13, 2026Jan 13, 2026Sep 19, 2033phase 2 · NCT07387926

Also a collaborator on its studies: BeOne Medicines, Merck and Amgen Astellas Biopharma.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and studies of Imugene only; the figures above count every company.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 14, 2023First study: phase 1 study in Bites and StingsFirst studyNCT06063317 · 25 enrolled · United States

TargetBeta

CD19 →CD3E →read by rule
“T cell surface glycoprotein CD3 cross-linking agent; B-lymphocyte antigen CD19 cross-linking agent”ChEMBL 37, by rule

Other programs on the same two targets

ProgramCompanyFurthest phaseStudies
surovatamigAstraZenecaphase 310
Anti-CD19/CD3 Bispecific Antibody MK-1045Merckphase 38
YK012ruleexcyte-biopharma-ltdphase 25
GSK5926371GlaxoSmithKlinephase 22
Anti-CD19/CD3 T-cell Engaging Bispecific Antibody CLN-978rulecullinan-therapeutics-incphase 14
Anti-CD19/Anti-CD3/Anti-CD28 Trispecific Antibody CC312rulecytocares-incphase 14
Anti-CD19/Anti-CD3/Anti-CD2 Trispecific Antibody PIT565Novartisphase 13
ATG-201ruleantengene-biologics-limitedphase 11
KT501rulekali-therapeutics-incphase 11
KT502rulekali-therapeutics-incphase 11

Studies

The one study Imugene leads. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT06063317Bites and Stings · United States1TerminatedFeb 2, 202625

How it is read

Names in the registry

  • “Blinatumomab”, 25 entries
  • “MEDI-538”, 10 entries
  • “Blinatumomab (MT103)”, 2 entries
  • “blinatumomab”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.